Trial Profile
An Open-Label, Multi-Center, Dose-Escalation, Phase I Study With an Expansion Phase, to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6895882, an Immunocytokine, Consisting of a Variant of Interleukin-2 (IL-2v) Targeting Carcinoembryonic Antigen (CEA) Administered Intravenously, in Patients With Advanced and/or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cergutuzumab amunaleukin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Roche
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
- 11 Oct 2016 Results of the sub-study assessing selective and specific tumor targeting presented at the 41st European Society for Medical Oncology Congress
- 01 Sep 2016 Status changed from recruiting to completed.